TCP
INSM icon

Tourbillon Capital Partners’s Insmed INSM Stock Holding History

Tourbillon Capital Partners’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200,000
Closed -$4M – 99
2014
Q2 		$4M Buy
+200,000
New +$2.96M 0.23% 57

Other funds holding INSM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tourbillon Capital Partners's INSM Position: Q1 2016 in Review

Tourbillon Capital Partners sold out of Insmed (INSM) in Q1 2016, closing a stake of 530,263 shares — an estimated $9.62M sold.

Tourbillon Capital Partners first reported a position in INSM in Q4 2013 and held it in 9 quarters. The position peaked at $26M in Q1 2015. 101 funds tracked by Wall St. Rank hold INSM as of Q1 2016.

  • Tourbillon Capital Partners reported no remaining Insmed position as of Q1 2016 after selling out during the quarter.
  • Tourbillon Capital Partners sold 530,263 Insmed shares in Q1 2016, an estimated $9.62M.
  • Tourbillon Capital Partners first reported a position in Insmed in Q4 2013 and held it in 9 quarters.
  • Tourbillon Capital Partners's Insmed position peaked at $26M in Q1 2015.
  • 101 funds tracked by Wall St. Rank held Insmed as of Q1 2016.

Based on Tourbillon Capital Partners's 13F filing for Q1 2016, filed 16 May 2016.